West Pharmaceutical
323 hedge funds and large institutions have $6.86B invested in West Pharmaceutical in 2018 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 102 increasing their positions, 118 reducing their positions, and 36 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
11% more capital invested
Capital invested by funds: $6.2B → $6.86B (+$659M)
6% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 36
0% more funds holding
Funds holding: 323 → 323 (0)
1.07% less ownership
Funds ownership: 94.99% → 93.92% (-1.1%)
14% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 118
14% less call options, than puts
Call options by funds: $1.7M | Put options by funds: $1.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bessemer Group
Woodbridge,
New Jersey
|
+$86.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$75.1M |
| 3 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$44.6M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$29.3M |
| 5 |
UIM
USS Investment Management
London,
United Kingdom
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Select Equity Group
New York
|
-$149M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$44.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$28.2M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$19.3M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$18M |
WST Hedge Fund Activity: Q2 2018 in Review
323 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2018, worth a combined $6.86B — up 11% from $6.2B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new WST positions and 36 closed out — a net gain of 2 holders — while 102 added to existing stakes and 118 trimmed.
The largest buyer was Bessemer Group, adding an estimated $86.9M. The largest seller was Select Equity Group, cutting an estimated $149M.
- 323 institutional investors held West Pharmaceutical (WST) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $6.86B of West Pharmaceutical stock for Q2 2018, up 11% quarter-over-quarter.
- 38 funds opened new West Pharmaceutical positions in Q2 2018 and 36 closed out, a net change of +2 holders.
- The largest West Pharmaceutical buyer in Q2 2018 was Bessemer Group, an estimated $86.9M added.
- The largest West Pharmaceutical seller in Q2 2018 was Select Equity Group, an estimated $149M sold.
Based on aggregated 13F filings for Q2 2018.